In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...
Read More
In a nutshell This study examined infection rates after autologous stem cell transplantation in multiple myeloma patients. 1.2% in-hospital deaths were recorded in this study. All were caused by an infection following the stem cell transplant. Some background Autologous stem cell transplantation after high-dose chemotherapy has resulted in...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of a combination of panobinostat (Farydak), gemcitabine (Gemzar), busulfan (Busulfex), and melphalan (Alkeran), and a stem cell transplant in treating multiple myeloma. The primary outcome will be measured by the time until the disease progresses. This trial is being conducted in...
Read More
In a nutshell This study examined the effects of pomalidomide (Pomalyst) in combination with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed or refractory multiple myeloma. This treatment combination was considered safe and effective for previously treated multiple myeloma. Some background Standard treatment for...
Read More
In a nutshell This study examined the safety and effectiveness of pomalidomide (Pomalyst) for multiple myeloma patients who have received multiple prior therapies. Researchers reported improved treatment outcomes when pomalidomide was combined with the steroid drug dexamethasone (Decadron) compared to pomalidomide alone. Some background Standard...
Read More
In a nutshell This study examined the safety of combining a biologic therapy (pomalidomide [Pomalyst]), a targeted therapy (carfilzomib [Kyprolis]), and a steroid drug (dexamethasone [Decadron]) for relapsed or refractory multiple myeloma. Researchers reported early results on the safety and potential effectiveness of this treatment combination. Some...
Read More
In a nutshell This study examined the safety and effectiveness of elotuzumab (Empliciti) for relapsed multiple myeloma. Researchers concluded that elotuzumab combined with lenalidomide (Revlimid) and dexamethasone was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background Standard...
Read More
